kotak-logo
Beta Drugs Share Price

Beta Drugs Share Price

1098
+30.20 (2.83%)
BETA • 06 Mar, 2026 | 03:29 PM

1Y Annualised Return

-38.31%

3Y Annualised Return

19.93%

5Y Annualised Return

55.01%

Beta Drugs Stock Performance

1W Return4.41
1Y Return-36.56
Today's Low1051.8
Prev. Close1,067.80
Mkt Cap (Cr.)1,113.03
1M Return-20.42
3Y Return69.79
52-Week High2000
Open1,051.80
PE Ratio107.12
6M Return-42.21
Today's High1108.1
52-Week Low990.1
Face Value10

Beta Drugs Company background

Founded in: 2005
Managing director: Rahul Batra
Beta Drugs Limited was incorporated as a private limited company with the name Beta Drugs Private limited at Himachal Pradesh on September 21, 2005. Subsequently, the company was converted in to public limited company and the name of the company was changed to Beta Drugs Limited on August 11, 2017 Beta Drugs is a part of Adley Group. Adley Group was founded in the year 1985, by its promoter Vijay Batra, who has more than twenty five years of experience in manufacture of pharmaceutical products in India. The Company is a pharmaceutical formulation manufacturing company engaged in developing, manufacturing and marketing of drug products for domestic and international customers. The Promoter Vijay Batra, took over the company from Kiran Goyal, Deepak Kumar Prince Bharti and Rohit Bansal in the year 2014. The company is primarily engaged in the manufacturing of oncology products. The Companys products range from anticancer tablets, capsules, injections and lyophilized injections. The Company started production of oncology products by manufacturing portfolio of over 35 products which is used for the treatment of various cancer disease. The Company set up the first Oncology Unit in Adley Formulations Pvt Ltd. in 2008. It set up a new state of the art manufacturing facility for oncology formulations in 2014 developed inhouse Albumin bound Paclitaxel in 2015 started inhouse API Plant Adley Labs in 2017. In October, 2017, the Company came up with a Public Issue of 22,96,000 Equity Shares by raising equity capital aggregating Rs 19.5 Crores.The Company set up an Oncology Plant in Uzbekistan in 2018. In 2020, the Company launched GEMRTU, ADLEAP, ADLANTE, BEXINIB launched 1st Indian Brand of Dasatinib, BEEDAN. In 2025, the Company launched 1st Indian brand of Sunitinib, ADSUNIB.

Beta Drugs Financial Highlights


For the full year FY2025–2026, revenue reached ₹368.79 crore and profit touched at ₹42.42 crore.

Beta Drugs Share Price Today


As of 7 Mar 2026, Beta Drugs share price is ₹1098. The stock opened at ₹1051.8 and had closed at ₹1067.8 the previous day. During today’s trading session, Beta Drugs share price moved between ₹1,051.80 and ₹1,108.10, with an average price for the day of ₹1079.95. Over the last 52 weeks, the stock has recorded a low of ₹990.10 and a high of ₹2,000.00. In terms of performance, Beta Drugs share price has declined by 42.2% over the past six months and has declined by 38.31% over the last year.
Read More
Beta Drugs SIP Return Calculator
5,000
Over the past
Total Investment of ₹3,00,000
Monthly SIP of 5,000 would have become 15,65,243 in 5 years with a gain of 12,65,243 (+421.75%)
View details of Market Depth

Beta Drugs Fundamental

Market Cap (in crs)

1,113.03

Face Value

10

Turnover (in lacs)

78.36

Key Metrics

Qtr Change %
45.10% Fall from 52W High
-32.7
Dividend yield 1yr %
0

Beta Drugs Key Financials

View more
Loading chart...
Beta Drugs Quarterly Revenue
Beta Drugs Yearly Revenue
Beta Drugs Quarterly Net Profit/Loss
Beta Drugs Yearly Net Profit/Loss

Beta Drugs Result Highlights

  • Beta Drugs Ltd reported a - quarter-on-quarter (QoQ) - in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a - of -.

  • Its expenses for the quarter were - by - QoQ and - - YoY.

  • The net profit - - QoQ and - - YoY.

  • The earnings per share (EPS) of Beta Drugs Ltd stood at 8.4 during Q3 FY 2025-26.

    Read more

Data Source: BSE, Company announcements

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

Beta Drugs Technical Analysis

Moving Averages Analysis
1098
Current Price
Bullish Moving Averages
4
Bearish Moving Averages
12
Day EMA5
1,072.50
Day EMA10
1,087.80
Day EMA12
1,100.90
Day EMA20
1,161.50
Day EMA26
1,204.50
Day EMA50
1,332.40
Day EMA100
1,477.30
Day EMA200
1,588.70
Delivery & Volume
Loading chart...

Day

52.20%

Week

70.30%

Month

56.30%

Delivery & Volume

1,085.97
Pivot
Resistance
First Resistance
1,120.13
Second Resistance
1,142.27
Third Resistance
1,176.43
Support
First Support
1,063.83
Second support
1,029.67
Third Support
1,007.53
Relative Strength Index
33.05
Money Flow Index
20.21
MACD
-103.60
MACD Signal
-111.41
Average True Range
70.53
Average Directional Index
42.36
Rate of Change (21)
-24.63
Rate of Change (125)
-41.74
Compare

Beta Drugs Shareholding Pattern

Promoter
64.9%
Foreign Institutions
1.1%
Domestic Institutions
1.9%
Public
32.1%

Beta Drugs Latest News

21 NOV 2025 | Friday
22 MAR 2025 | Saturday
27 NOV 2024 | Wednesday

Please be aware that Beta Drugs stock prices are subject to continuous fluctuations due to various factors.